Introduction
Chronic lymphocytic leukemia (CLL) accounts for 25% to 30% of all leukemias and is the most prevalent type of leukemia in the Western world. Despite major advances in our understanding of the genetics, biology, diagnosis, clinical staging, and management of CLL, 1-5 the overall median survival of CLL patients remains approximately 6 years and is shorter for patients in the high-risk group. The disease is characterized by the progressive accumulation of long-lived malignant B cells with a characteristic CD19 ϩ CD5 ϩ CD23 ϩ BCR low phenotype. These B-CLL cells accumulate in the G 0 phase of the cell cycle with a low proliferative index and have acquired resistance to apoptosis via aberrant up-regulation of prosurvival mechanisms. [6] [7] [8] [9] [10] Because B-CLL cells do not divide at a high rate, they are less susceptible to radiation therapy and chemotherapy. Alternative therapeutic approaches are needed to achieve longer survival and ultimately a cure in CLL patients. Immunotherapy is a promising approach for the treatment of CLL. 11-15 B-cell surface differentiation antigens and receptors can serve as tissue-specific targets for immunotherapy. Antibodies (Abs), such as the anti-CD20 (rituximab), [16] [17] [18] the anti-CD52 (alemtuzumab, Campath-1H), [19] [20] [21] and the anti-CD40 antagonist Ab (HCD122), 22 are being used clinically to achieve a complete and prolonged remission in CLL patients. However, most CLL patients who undergo antibody-based treatments eventually relapse. New immunotherapeutic strategies are needed to effectively prevent and treat leukemia recurrences.
Toll-like receptors (TLRs) are pattern recognition receptors that trigger innate and adaptive immune responses. The human TLR family includes 10 different TLRs that compose an elegant pathogen recognition system for host defense in innate immunity. 23 Triggering TLRs activates a set of common proinflammatory genes and leads to the expression of antimicrobial effector molecules as well as inflammatory cytokine production. Agonists for human TLR1 to TLR9 have been identified and are being developed as new drugs and vaccine adjuvants to treat cancer, allergies, and infectious diseases. 24, 25 We are interested in exploring TLRtargeted immunotherapy of CLL with TLR agonists and in elucidating the molecular mechanism(s) underlying TLR agonistmediated antitumor effects. Although the TLR expression profile in human B-CLL cells is unknown, studies have shown that TLR9 agonists, CpG oligodeoxynucleotides (CpG ODN), can activate B-CLL cells to up-regulate cell surface expression of costimulatory molecules and induce cytokine production. 26, 27 In this study, we show that human B-CLL cells express high levels of TLR9. Triggering TLR9 with CpG-B ODN leads to nuclear factor-B (NF-B)-dependent production of autocrine interleukin-10 (IL-10), which activates JAK/STAT pathway-dependent tyrosine phosphorylation of signal transducer and activator of transcription 1 (STAT1) and thereby provokes an apoptotic death pathway in B-CLL cells.
Methods

Cell preparations
Blood samples from 23 untreated CLL patients were drawn after obtaining written informed consent approved by the University of Minnesota Institutional Review Board in accordance with the Declaration of Helsinki. The sex, age, Rai stage, percentage of blood CD5 ϩ CD19 ϩ CD23 ϩ B-CLL cells, and cytogenetic and mutational status of these CLL patients are summarized in Table 1 . Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque density gradient centrifugation. B-CLL cells in PBMCs were purified using untouched B-cell isolation kit (Miltenyi Biotec) to more than 95% of CD5 ϩ CD19 ϩ cells. Normal B and T cells were purified from PBMCs of healthy blood donors using B-cell or T-cell isolation kit (Miltenyi Biotec) to more than 98% of CD19 ϩ cells or CD3 ϩ cells, respectively.
CpG oligodeoxynucleotides
Phosphorothioated unmethylated type A CpG ODNs (2216, 5Ј-ggGGGACGATCGTCgggggG-3Ј; PB4, 5Ј-tcgGACGATCGTCgggggG-3Ј; 1002, 5Ј-ggGGTCGTTCGTCGTTgggggG-3Ј) and type B CpG ODNs (2006, 5Ј-tcgtcgttttgtcgttttgtcgtt-3Ј; 684, 5Ј-tcgacgttcgtcgttcgtcgttc-3Ј; 685, 5Ј-tcgtcgacgtcgttcgttctc-3Ј) were purchased from Intergrated DNA Technologies. Lowercase letters represent phosphorothioate linkage, and upper letters represent phosphodiester linkage. CpG ODNs were resuspended in Tris-ethylenediaminetetraacetic acid buffer, diluted in phosphate-buffered saline (PBS), and tested at a final concentration of 5 g/mL or as indicated.
RT-PCR for TLRs
RNA was extracted from 2 ϫ 10 6 purified B-CLL, normal B, or T cells, reversely transcribed to cDNA, and analyzed for TLR1-10 expression and real-time reverse-transcribed polymerase chain reaction (RT-PCR) for TLR9 expression. All PCR parameters and primer sequences for TLR1 to TLR-10 and ␤-actin were as published. 28 All RT-PCR reagents were from Invitrogen.
B-CLL cell cultures
To determine the immune-stimulatory effects of CpG ODNs, purified B-CLL cells (1 ϫ 10 6 /well) were cultured in 10% human AB serum RPMI 1640 media with or without CpG ODN in 48-well plates. After 3 days, cells were harvested and assessed for morphologic changes by Giemsa staining 29 and for phenotypic changes by flow cytometry. To determine CpG ODN treatment time or doses on apoptosis induction, B-CLL cells (2 ϫ 10 5 /well) were cultured in media with or without CpG ODNs at 5 g/mL for up to 9 days or at different doses (0.1-10 g/mL) for 5 days in 96-well plates. Several wells of B-CLL cells from each culture condition were harvested at the indicated time points, counted, and stained with tetramethyl-rhodamine ethylester (TMRE, Invitrogen) or annexin V-FITC Apoptosis Detection Kit I (BD Biosciences). To determine the minimum treatment dose and exposure time required for CpG ODNs to achieve a 50% reduction of leukemia cells, B-CLL cells (4 ϫ 10 5 /well) were cultured in 96-well plates in media with different concentrations of CpG ODNs for the indicated exposure time lengths. At the end of each designated treatment time point, cells were washed twice in the wells, resuspended in fresh media, and continued in culture for a total of 7 days. B-CLL cells of all treatment groups were then harvested, counted, stained with TMRE, and determined by flow cytometry. Viable B-CLL cell number was calculated by multiplying total cell counts with the percentage of TMRE-positive cells of each culture condition.
Flow cytometry
Cell surface markers were analyzed by staining with fluorescent Abs against CD3, CD5, CD19, CD23, CD40, CD45, CD54, CD80, CD86, HLA-ABC, HLA-DR, or isotype control Ab (BD Biosciences). Apoptotic B-CLL cells were assessed by TMRE or annexin V/propidium iodide (PI) staining. Mean fluorescence intensity (MFI) and positive cell percentages were determined. For personal use only. at UNIV OF CALIFORNIA DAVIS on January 21, 2011. www.bloodjournal.org From T-cell proliferation assay B-CLL cells cultured with or without CpG ODNs for 3 days were irradiated at 30 Gy and used as stimulators to purified allogeneic T cells (1 ϫ 10 5 / well) in mixed leukocyte reaction (MLR) assays. Plates were incubated at 37°C for 5 days and pulsed with 1 Ci/well of 3 H-thymidine for the last 18 hours before harvesting. All determinations were conducted in triplicate and 3 H-thymidine incorporation (cpm) was determined.
NOD-scid mouse xenograft models
Eight-week-old female NOD-scid IL2R␥ null mice, a NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ mouse strain that lacks of T, B, and natural killer ( 
Western blots
Protein lysates were prepared from 5 ϫ 10 6 purified B-CLL, normal B, and T cells. Western blot was performed using primary Abs specific for TLR9, total, tyrosine-or serine-phophorylated STAT1 (Santa Cruz Biotechnology), cleaved caspase-3, caspase-9, or poly(ADP-ribose) polymerase (PARP; Cell Signaling Technology), respectively, and secondary antirabbit IgG-horseradish peroxidase (Santa Cruz Biotechnology), and visualized by enhanced chemiluminescence (Pierce Chemical). Blots were reprobed with an anti-␤-actin Ab (Santa Cruz Biotechnology) as a loading control. Signals intensity was quantified using a Fluorochem 8000 imaging system (Alpha Innotech).
Assays for blocking CpG ODN-induced apoptosis of B-CLL cells
To block apoptosis with caspase inhibitors, B-CLL cells (2 ϫ 10 5 /well) were pretreated with 20M pan-caspase, caspase-3, or caspase-9 inhibitor (R&D Systems) for 2 hours in 96-well plates and cultured in media with CpG 2006. To block apoptosis with inhibitors specific for NF-B and JAK/STAT pathways, B-CLL cells were pretreated with 5 g/mL caffeic acid phenethyl ester (CAPE) and/or 50M AG490 (Calbiochem) for 1 hour and cultured in media with or without CpG 2006. Kinetic expressions of tyrosine-or serine-phosphorylated STAT1 were determined by Western blot. Culture supernatants at 72 hours were assessed for cytokine production. AG490 pretreatment on CpG 2006-induced cleavage of caspase-9, caspase-3, and PARP in B-CLL cells were determined at day 5 by Western blots. To block apoptosis with STAT1 antisense ODN, B-CLL cells were pretreated with 12.5M STAT1 phosphorothioated antisense ODN (5Ј-CCACTGAGACATCCTGCCACC-3Ј) 30 or sense ODN (5Ј-GGTGGCAG-GATGTCTCAGTGG-3Ј) from Operon Biotechnologies for 24 hours and cultured in media with or without CpG 2006. Total, tyrosine-or serinephosphorylated STAT1 expression was assessed by Western blot at 0, 24, and 48 hours. B-CLL cells in cultures were assessed for phenotypic changes at day 3 and apoptosis at day 5.
Cytokine assays
Serum-free culture supernatants from B-CLL cells incubated with or without CpG 2006 were collected at 72 hours or the indicated time points and assessed for cytokines. IL-1␤, IL-2, IL-4, IL-6, IL-8, IL-10, interferon-␥ (IFN-␥), tumor necrosis factor-␣ (TNF-␣), granulocyte colonystimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and vascular endothelial growth factor (VEGF) were assayed with the Fluorokine MAP immunoarray (R&D Systems) using the Luminex 100 analyzer. IFN-␣, IFN-␤, and transforming growth factor-␤1 (TGF-␤1) were determined by enzyme-linked immunosorbent assay (R&D Systems). The lower limits of each cytokine detection were as follows (pg/mL): IL-1␤, 0.15; IL-2, 0.2; IL-4, 0.7; IL-6, 0.5; IL-8, 0.2; IL-10, 0.3; IFN-␥, 4.0; TNF-␣, 0.4; G-CSF, 1.0; GM-CSF, 2.0; VEGF, 0.4; IFN-␣, 3.0; IFN-␤, 50; TGF-␤1, 4.6. The background level of TGF-␤1 in serum-free medium alone is at 200 pg/mL.
Neutralizing IL-10 in B-CLL cell cultures
Anti-IL-10 (10 g/mL) or anti-TNF-␣ (10 g/mL) Ab (R&D Systems) was added to B-CLL cell cultures with or without CpG 2006. The expression of tyrosine-or serine-phosphorylated STAT1 in B-CLL cells was assessed by Western blot at the indicated time points. In some experiments, graded doses (0.02-50.0 ng/mL) of exogenous rh-IL-10 (R&D Systems) were added to B-CLL cell cultures with or without the presence of anti-IL-10 or anti-TNF-␣ Ab. B-CLL cells in cultures with or without CpG 2006 and/or rh-IL-10 (5 ng/mL) were assessed for phenotypic changes at day 3 and apoptosis at day 5. Tyrosine-or serine-phosphorylated STAT1 expression in B-CLL cells cultured with or without IL-10 (5 ng/mL) in the presence or absence of anti-IL-10 Ab (10 g/mL) were determined by Western blot at 24 hours.
Data analysis
Data from experiments are expressed as the mean plus or minus SD. Statistical analysis of the results between groups was performed by Student t test. Values of P less than .05 were considered significant.
Results
Human B-CLL cells express high levels of TLR9 and can be potently activated by CpG-B ODNs
B-CLL cells from blood samples of CLL patients express a characteristic CD19 ϩ CD5 ϩ CD23 ϩ malignant B-cell phenotype. Like normal B cells, B-CLL cells expressed TLR1, TLR6, TLR7, TLR9, and TLR10 ( Figure 1A ; and data not shown). Real-time RT-PCR results showed that TLR9 gene expression was significantly higher (3.2-fold) in B-CLL cells than in normal B cells ( Figure 1B) . Western blot analysis confirmed that TLR9 protein expression was 3.5-fold higher in B-CLL cells than in normal B cells ( Figure 1C) . To study the immune-stimulatory effects of TLR9 agonists on B-CLL cells, 2 distinctive classes of CpG-A and CpG-B ODNs 31 were used. Freshly isolated B-CLL cells display a typical leukemic B-cell morphology ( Figure 1D) . B-CLL cells cultured in media alone or with CpG-A ODN (CpG 2216) displayed a typical CLL morphology with cytologic features similar to that of fresh B-CLL cells. In contrast, CpG-B ODN (CpG 2006)-stimulated B-CLL cells formed aggregated cell clusters and underwent dramatic cytologic changes with marked cellular enlargement and abundant basophilic cytoplasm within 3 days in culture ( Figure 1D ). Fresh B-CLL cells are positive for HLA-ABC and HLA-DR but express negligible levels of CD40, CD54, CD80, and CD86. B-CLL cells cultured in media or with CpG 2216 for 3 days only modestly increased B-CLL cell surface expression of CD54, CD86, and HLA-DR (2.9-, 2.5-, and 2.2-fold, respectively). In contrast, more substantial and significant increases of surface expression of CD40, CD54, CD86, HLA-ABC, HLA-DR (11.5-, 12.5-, 5.2-, 4.5-, and 4.6-fold, respectively) on B-CLL cells were detected within 3 days after CpG 2006 stimulation ( Figure 1E-F) . We have comparatively tested additional CpG-A and CpG-B ODNs and consistently found that CpG-B ODNs strongly activate, whereas CpG-A ODNs weakly activate, B-CLL cells to up-regulate Figure 2D ). We also found that apoptotic B-CLL cells (R1 gate) lost their characteristic expression of CD23 and decreased surface expression of CD5 and CD19, whereas viable B-CLL cells (R2 gate) remained positive for CD23 (data not shown). B-CLL cells from 5 patients (patients 6, 10, 15, 17, and 20) were insensitive to CpG-B ODN treatment. Further studies are needed to determine whether B-CLL cells insensitive to CpG-B ODN treatment are from specific cytogenetic CLL subgroups and potentially correlate with the presence of certain cytogenetic aberrations. Nevertheless, these findings demonstrate that CpG-B ODN triggering of TLR9 activates B-CLL cells to undergo apoptosis.
CpG-B ODN-induced apoptosis of B-CLL cells is treatment time-and dose-dependent
Purified B-CLL cells were incubated with graded doses of CpG ODNs in a 5-day culture. CpG-B ODNs (2006 or 685) but not CpG-A ODNs (2216 or PB4) potently induced apoptosis and decreased B-CLL cell number in a CpG ODN dose-dependent manner ( Figure 3A) . A 50% reduction of B-CLL cells was achieved with just 12-to 24-hour exposure to CpG 2006 or CpG-B 685 at 3 g/mL but was unachievable with the same dose of CpG 2216 or CpG PB4 at all treatment time points up to 7 days ( Figure 3B) . A 50% reduction of B-CLL cells was also achieved with 48-hour exposure to CpG 2006 or CpG 685 at 1 g/mL but was unachievable when the dose of CpG 2006 or CpG 685 dropped to 0.3 g/mL or lower in the 7-day culture ( Figure 3C ). These findings demonstrate that CpG-B ODN-induced apoptosis of B-CLL cells is treatment time-and dose-dependent. Figure 5B ). These findings demonstrate that TLR9 signaling by CpG ODN activates the apoptotic pathway elements in B-CLL cells committing them to death, and this effect can be inhibited by specific caspase inhibitors.
TLR9 uses a myeloid differentiation factor 88-dependent pathway to induce expression of NF-B-dependent target genes that promote inflammatory responses and cytokine production. Figure 5C ). These findings suggest that apoptosis induced by TLR9-CpG ODN ligation is dependent on the NF-B and JAK/STAT signaling pathways. Preventing apoptosis by AG490 suggests that CpG ODN-induced apoptosis probably occurs via an indirect mechanism involving autocrine cytokines that provoke apoptosis of B-CLL cells. For personal use only. at UNIV OF CALIFORNIA DAVIS on January 21, 2011. www.bloodjournal.org From
